Quotient Bioresearch signs agreement with Cambridge Research Biochemicals

Quotient Bioresearch provides early stage and specialist drug development services to pharmaceutical, biotechnology and medical device clients worldwide.

Peptides which have been site-specifically labeled with tritium are ideal for use in receptor studies.

Tritium labeling does not change the chemical structure of the peptide, producing labeled ligands with chemical and biological properties identical to those of the unlabelled molecule.

Quotient Bioresearch Chemistry & Metabolism MD Stephen Lewinton said this formalized agreement will combine the expertise of both companies to give customers an improved service to obtain custom manufactured hot and cold peptides.

Cambridge Research Biochemicals Commercial Director Emily Humphrys said the strategic alliance with Quotient is a major benefit to customers as it will provide a seamless operation for their Piquant Peptides (‘hot’) radio labeled peptide offering.